Valuation: Inotiv, Inc.

Market Cap 4L 3L 3L 3L 5L 3.71Cr 6L 38.41L 14.88L 1.9Cr 14.54L 14.23L 6.09Cr P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 44Cr 38Cr 36Cr 33Cr 62Cr 4.2TCr 62Cr 434.32Cr 168.22Cr 2.14TCr 164.43Cr 160.87Cr 6.89TCr EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-7.50%
6 months-95.93%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.62
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/07/26 Others

Chief Executive Officer

-13,61,215 3.9017%
19/07/26 Others

Director

-7,29,626 2.0913%
19/07/26 Others

Chief Financial Officer

-1,39,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.20%-99.63% 4L
-0.14%+4.33%+9.00%+31.64% 4.8TCr
-1.69%+1.48%+50.57%+34.53% 4.45TCr
+2.56%+7.34%+366.69%+608.26% 4.39TCr
+0.24%+2.85%+10.67%+94.47% 4.1TCr
-0.62%-1.11%+4.65%+48.91% 2.99TCr
-0.28%+1.07%+24.58%+155.58% 1.73TCr
+3.37%+9.21%+8.32% - 1.53TCr
-0.46%+1.20%+26.90%+42.21% 1.53TCr
-2.21%-4.70% - - 1.48TCr
Average -2.52%-1.72%+44.69%+114.49% 2.7TCr
Weighted average by Cap. +0.11%+2.86%+79.67%+160.28%

Financials

2024 2025
Net sales 49Cr 43Cr 41Cr 37Cr 69Cr 4.7TCr 70Cr 486.69Cr 188.5Cr 2.4TCr 184.25Cr 180.27Cr 7.72TCr 51Cr 45Cr 43Cr 39Cr 73Cr 4.92TCr 73Cr 508.79Cr 197.06Cr 2.51TCr 192.62Cr 188.45Cr 8.07TCr
Net income -11Cr -9.52Cr -8.99Cr -8.19Cr -15Cr -1.04TCr -15Cr -107.55Cr -42Cr -531Cr -41Cr -40Cr -1.71TCr -6.86Cr -6.02Cr -5.69Cr -5.18Cr -9.7Cr -657.73Cr -9.77Cr -68Cr -26Cr -336.02Cr -26Cr -25Cr -1.08TCr
Net Debt 42Cr 37Cr 35Cr 32Cr 60Cr 4.06TCr 60Cr 420.19Cr 162.75Cr 2.07TCr 159.08Cr 155.64Cr 6.67TCr 44Cr 38Cr 36Cr 33Cr 62Cr 4.19TCr 62Cr 433.93Cr 168.07Cr 2.14TCr 164.28Cr 160.73Cr 6.89TCr
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock